Shah MM - Search Results

1

An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.

Shah MM, Dobbin ZC, Nowsheen S, Wielgos M, Katre AA, Alvarez RD, Konstantinopoulos PA, Yang ES, Landen CN. Shah MM, et al. Gynecol Oncol. 2014 Aug;134(2):331-7. doi: 10.1016/j.ygyno.2014.05.009. Epub 2014 May 15. Gynecol Oncol. 2014. PMID: 24844596 Free PMC article.

2

Smoothened antagonists reverse taxane resistance in ovarian cancer.

Steg AD, Katre AA, Bevis KS, Ziebarth A, Dobbin ZC, Shah MM, Alvarez RD, Landen CN. Steg AD, et al. Among authors: shah mm. Mol Cancer Ther. 2012 Jul;11(7):1587-97. doi: 10.1158/1535-7163.MCT-11-1058. Epub 2012 May 2. Mol Cancer Ther. 2012. PMID: 22553355 Free PMC article.

3

Ovarian cancer stem cells: are they real and why are they important?

Shah MM, Landen CN. Shah MM, et al. Gynecol Oncol. 2014 Feb;132(2):483-9. doi: 10.1016/j.ygyno.2013.12.001. Epub 2013 Dec 7. Gynecol Oncol. 2014. PMID: 24321398 Free PMC article. Review.

4

Using heterogeneity of the patient-derived xenograft model to identify the chemoresistant population in ovarian cancer.

Dobbin ZC, Katre AA, Steg AD, Erickson BK, Shah MM, Alvarez RD, Conner MG, Schneider D, Chen D, Landen CN. Dobbin ZC, et al. Among authors: shah mm. Oncotarget. 2014 Sep 30;5(18):8750-64. doi: 10.18632/oncotarget.2373. Oncotarget. 2014. PMID: 25209969 Free PMC article.

5

Endoglin (CD105) contributes to platinum resistance and is a target for tumor-specific therapy in epithelial ovarian cancer.

Ziebarth AJ, Nowsheen S, Steg AD, Shah MM, Katre AA, Dobbin ZC, Han HD, Lopez-Berestein G, Sood AK, Conner M, Yang ES, Landen CN. Ziebarth AJ, et al. Among authors: shah mm. Clin Cancer Res. 2013 Jan 1;19(1):170-82. doi: 10.1158/1078-0432.CCR-12-1045. Epub 2012 Nov 12. Clin Cancer Res. 2013. PMID: 23147994 Free PMC article.

6

Does a standardized preoperative algorithm of clinical data improve outcomes in patients with ovarian cancer? A quality improvement project.

Shah MM, Leath CA 3rd, Daily LR, McGwin G Jr, Estes JM, Alvarez RD, Straughn JM Jr. Shah MM, et al. Int J Gynecol Cancer. 2015 Jun;25(5):798-801. doi: 10.1097/IGC.0000000000000433. Int J Gynecol Cancer. 2015. PMID: 25950127 Free PMC article.

7

Diabetes mellitus and ovarian cancer: more complex than just increasing risk.

Shah MM, Erickson BK, Matin T, McGwin G Jr, Martin JY, Daily LB, Pasko D, Haygood CW, Fauci JM, Leath CA 3rd. Shah MM, et al. Gynecol Oncol. 2014 Nov;135(2):273-7. doi: 10.1016/j.ygyno.2014.09.004. Epub 2014 Sep 16. Gynecol Oncol. 2014. PMID: 25220626 Free PMC article.

8

Reasons for failure to deliver National Comprehensive Cancer Network (NCCN)-adherent care in the treatment of epithelial ovarian cancer at an NCCN cancer center.

Erickson BK, Martin JY, Shah MM, Straughn JM Jr, Leath CA 3rd. Erickson BK, et al. Among authors: shah mm. Gynecol Oncol. 2014 May;133(2):142-6. doi: 10.1016/j.ygyno.2014.02.006. Epub 2014 Feb 8. Gynecol Oncol. 2014. PMID: 24517876 Free PMC article.

9

Do differences in medical comorbidities and treatment impact racial disparities in epithelial ovarian cancer?

Dilley S, Erickson BK, Phillips CE, Kennemer CR, Zhang B, Matin T, Martin JY, Shah MM, Michael Straughn J Jr, Leath CA 3rd. Dilley S, et al. Among authors: shah mm. Gynecol Oncol. 2018 Apr;149(1):49-52. doi: 10.1016/j.ygyno.2017.10.035. Gynecol Oncol. 2018. PMID: 29605050 Free PMC article.

10

The role of Notch and gamma-secretase inhibition in an ovarian cancer model.

Shah MM, Zerlin M, Li BY, Herzog TJ, Kitajewski JK, Wright JD. Shah MM, et al. Anticancer Res. 2013 Mar;33(3):801-8. Anticancer Res. 2013. PMID: 23482747 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

398 results

Search Page

Filters